35 results about "Feline immunodeficiency virus" patented technology

Attenuated recombinant viruses containing DNA encoding an immunodeficiency virus and/or CTL antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: HIV1gag(+pro)(IIIB), gp120(MN)(+transmembrane), nef(BRU)CTL, pol(IIIB)CTL, ELDKWA or LDKW epitopes, preferably HIV1gag(+pro)(IIIB), gp120(MN) (+transmembrane), two (2) nef(BRU)CTL and three (3) pol(IIIB)CTL etpitopes; or two ELDKWA in gp120 V3 or another region or in gp160. The two (2) nef(BRU)CTL and three (3) pol(IIIB)CTL epitopes are preferably CTL1, CTL2, pol1, pol2 and pol3. The recombinant viruses and gene products therefrom and antibodies generated by the viruses and gene products have several preventive, therapeutic and diagnostic uses. DNA from the recombinant viruses are useful as probes or, for generating PCR primers or for immunization. Also disclosed and claimed are HIV immunogens and modified gp160 and gp120.

Feline immunodeficiency virus antigens from gp160 envelope protein, gp120 envelope protein and p24 gag protein, useful for the diagnosis, treatment, and prevention of FIV. The invention may also be used to purify FIV.

This invention relates to C34 peptide derivatives having improved aqueous solubility that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory synctial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.

The present invention relates to a class of proteins, and a method for treatment of neurological and viral diseases in humans and animals. More specifically it applies to the treatment of heretofore intractable diseases such as retro-viral infections including human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) and equine acquired immunodeficiency virus (EAIV). The method of treatment comprises administering to the subject a disease mitigating amount of a detoxified modified venom composition.

The present invention relates to a class of proteins, a process of production thereof, and a method for treatment of neurological and viral diseases in humans and animals. More specifically it applies to the treatment of heretofore intractable diseases such as retro-viral infections including human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) and equine acquired immunodeficiency virus (EAIV). The

The present invention relates to a class of proteins, a process of production thereof, and a method for treatment of neurological and viral diseases in humans and animals. More specifically it applies to the treatment of heretofore intractable diseases such as retro-viral infections including human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) and equine acquired immunodeficiency virus (EAIV). The method of treatment comprises administering to the subject a disease mitigating amount of a detoxified and neurotropically active modified venom composition containing alpha-neurotoxins that target a nicotinic acetylcholine receptor.

The present disclosure provides methods and compositions for reducing the reservoir of latent immunodeficiency virus in an individual, and for treating an immunodeficiency virus infection in an individual.

The invention discloses a preparation method of an SIV (simian immunodeficiency virus) vector. A culture dish is treated with collagen by a calcium phosphate coprecipitation transfection process; and in the transfection process, an Opti-MEM culture medium is used, and the DNA (deoxyribonucleic acid) concentration is increased. The invention has the advantages of ingenious concept and low production cost; and the prepared tolvaptan tablet has the advantages of high in-vitro dissolution, high drug bioavailability and favorable clinical curative effect.

Method, device and kit for the detection of antibodies directed to Feline Immunodeficiency Virus (FIV). The method includes contacting the felid biological sample with FIV env polypeptide and detecting whether the polypeptide substantially binds to the antibody in the biological sample. The method will detect FIV antibodies in a sample from animals that have been naturally infected but the method will not detect antibodies in a sample from animals that have not been infected and that have not been vaccinated with an FIV vaccine after within about the previous five to eight weeks.

The invention relates to a nucleic acid combination product, a detection kit and a micro-fluidic chip. The nucleic acid combination product comprises at least two of the following detection primer pairs: a feline parvovirus primer pair, a feline coronavirus primer pair, a feline herpesvirus type I primer pair, a feline calicivirus primer pair, a feline leukemia virus primer pair, a feline immunodeficiency virus primer pair, a feline astrovirus primer pair, a feline rotavirus primer pair, a cat vaccinia virus primer pair and a cat reovirus primer pair. The nucleic acid combination product can be used for detecting at least two feline pathogenic viruses in the sample to be detected at one time, and is good in specificity and relatively high in detection sensitivity.

The invention relates to the technical field of biology, and particularly discloses a recombinant immunodeficiency plasmid and virus and application thereof. The immunodeficiency plasmid comprises LTR, gag gene, nucleotide sequence disclosed as SEQ ID No.1, vif gene, vpr gene, vpx gene, tat gene, rev gene, env gene and nef gene. The nucleotide sequence disclosed as SEQ ID NO.1 is introduced to the pathogenic SIVmac239 full-length plasmid frame to construct the immunodeficiency plasmid comprising a plurality of drug target spots, and packaging is performed in the 293T cell to generate immunodeficiency virus. The virus has the capacity for infecting target cells and the capacity of efficient replication, and is applicable to researching human immunodeficiency virus (HIV) in-vivo infection process, pathogeny characteristic, pathogenesis and immunoreaction and screening anti-HIV drugs and anti-HIV drug application strategies.

A chimeric type 5/type 11 or type 35 adenovirus vector, wherein a gene encoding the envelope protein of human immunodeficiency virus or its mutant having an equivalent function is integrated into a nonproliferation type 5 adenovirus in such a manner as allowing the expression and a gene encoding the fiber protein of the type 5 adenovirus is substituted by a gene encoding the fiber protein of a type 11 or type 35 adenovirus or a mutant having an equivalent function, has a lessened toxicity on the liver and can induce an extremely potent HIV-specific immune response. Thus, it is highly efficacious as a drug for preventing HIV-infection.

The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides a fusion protein comprising a viral chemokine fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing viral infection.

The invention mainly relates to immuno comb array test paper for detecting an antibody of an SIV (simian immunodeficiency virus) as well as a preparation method and an application. A recombinant plasmid pGEX-4T-SIV for establishment of an immuno comb array is shown in the sequence table Seq No.3. An upper primer SIVF in a primer pair for establishment of the recombinant plasmid is shown in the sequence table Seq No.1, and a lower primer SIVR of the primer pair is shown in the sequence table Seq No.2. The establishment method comprises the following steps: the SOE (splicing overlapping extension)-PCR (polymerase chain reaction) primer pair is designed according to the nucleotide sequence of the SIV, SIV genes are amplified through SOE-PCR, and the recombinant plasmid pGEX-4T-SIV is established; finally, the immuno comb array for quickly detecting the antibody in blood or serum of an experimental monkey is prepared with a film chromatographic technique according to the enzyme linked immunosorbent assay principle and has good stability, specificity, sensitivity and repeatability.

This invention is directed to a synthetic non-naturally occurring oligonucleotide compound which comprises nucleotides whose sequence defines a conserved catalytic region and nucleotides whose sequence is capable of hybridizing with a predetermined target sequence within a packaging sequence of an RNA virus. Preferably, the viral packaging sequence is a retrovirus packaging sequence or the HIV-1 Psi packaging sequence. The RNA virus may be HIV-1, Feline Leukemia Virus, Feline Immunodeficiency Virus or one of the viruses listed in Table I. The conserved catalytic region may be derived from a hammerhead ribozyme, a hairpin ribozyme, a hepatitis delta ribozyme, an RNAase P ribozyme, a group I intron, a group II intron. The invention is also directed to multiple ribozymes, combinations of ribozymes, with or without antisense, and combinations of ribozymes, with antisense, and TAR decoys, polyTARs and RRE decoys targeted against the RNA virus. Vectors are also described. Further, methods of treatment and methods of use both in vivo and ex vivo are described.

In some embodiments the present disclosure provides a method of inactivating a RNA virus of the family retroviridae in a biological sample. Such a method comprises contacting the biological sample with an effective amount of an antiviral composition comprising PD 404,182. In an embodiment of the present disclosure the RNA virus is selected from the group consisting of HIV pseudotyped lentiviruses, primary human immunodeficiency virus-1 isolates (HIV-1), human immunodeficiency virus-2 (HIV-2), and simian immunodeficiency virus (SIV). Further embodiments of the present disclosure pertain to a method of treating a subject infected by a RNA virus of the family retroviridae. Another embodiment of the present invention pertains to a method of preventing transmission of a RNA virus of the family retroviridae in a subject in need thereof.